Business
Appointment of Nominated Adviser and Joint Broker
Appointment of Nominated Adviser and Joint Broker.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8271F\n Cambridge Cognition Holdings PLC\n 24 March 2022\n \n \n \n \n Cambridge Cognition Holdings Plc\n \n \n \n \n \n (\"Cambridge Cognition\" or the \"Company\")\n \n \n \n \n \n Appointment of Nominated Adviser and Joint Broker \n \n \n \n \n \n Director \n \n Disclosures\n \n \n \n \n \n \n Cambridge Cognition Holdings (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the appointment of Panmure Gordon (UK) Limited (\"Panmure Gordon\") as the Company's Nominated Adviser and Joint Broker with immediate effect.\n \n \n \n \n \n The Company also announces the information in the Appendix below relating to additional director disclosures under Schedule Two, Paragraph (g) of the AIM Rules for Companies.\n \n \n \n For further information, contact:\n \n \n \n \n \n Cambridge Cognition Holdings Plc\n \n \n Matthew Stork, Chief Executive Officer\n \n \n Steven Powell, Chairman\n \n \n \n \n Tel: 012 2381 0700\n \n \n \n [email protected]\n \n \n \n \n \n \n \n Panmure Gordon (NOMAD and Joint Broker)\n \n \n Freddy Crossley / Emma Earl / Mark Rogers\n \n \n Rupert Dearden\n \n \n \n \n Tel: 020 7886 2500\n \n \n (Corporate Advisory)\n \n \n (Corporate Broking)\n \n \n \n \n \n \n Dowgate Capital Limited (Joint Broker)\n \n \n David Poutney / James Serjeant\n \n \n \n \n Tel: 020 3903 7715\n \n \n \n \n \n \n \n \n \n IFC Advisory Ltd (Financial PR and IR)\n \n \n Tim Metcalfe / Graham Herring / Zach Cohen\n \n \n \n \n Tel: 020 3934 6630\n \n \n \n \n \n \n \n \n \n \n \n Notes to Editors\n \n \n \n \n \n About Cambridge Cognition\n \n \n Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.\n \n \n \n \n \n For further information visit \n \n www.cambridgecognition.com\n \n \n \n Appendix\n \n \n \n \n The Company announces the following information relating to directors' disclosures pursuant to Schedule Two, paragraph (g) of the AIM Rules for Compan...